Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEMADRIN vs FLEXERIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting anticholinergic agent that blocks muscarinic receptors in the basal ganglia, reducing cholinergic overactivity and restoring dopamine-acetylcholine balance.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Adjunctive treatment of Parkinson's disease,Drug-induced extrapyramidal reactions (acute dystonic reactions, parkinsonism, akathisia)
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
2.5 mg orally three times daily, increased gradually to 5 mg three to four times daily if necessary; maximum 15-20 mg daily.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
6-10 hours in adults (terminal elimination half-life); may be prolonged in elderly or renal impairment.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Primarily metabolized by hepatic microsomal enzymes; metabolites are excreted in urine.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Primarily renal as unchanged drug and metabolites (approximately 50% unchanged); minor biliary/fecal elimination (<10%).
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
~90%, primarily to albumin and alpha-1-acid glycoprotein.
~93% bound to plasma proteins, primarily albumin.
4-8 L/kg; indicates extensive tissue distribution (high lipophilicity).
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Oral: ~80% with first-pass metabolism reducing systemic exposure.
Oral: ~33% due to extensive first-pass metabolism.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: administer every 6 hours. GFR <10 m L/min: avoid use or administer every 12 hours.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
Contraindicated in severe hepatic impairment. In mild to moderate (Child-Pugh A or B): use with caution, reduce dose or extend dosing interval.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Not established. Safety and efficacy in children under 12 years have not been determined.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Initiate at low end of dosing range (2.5 mg once or twice daily); increase slowly. Monitor for confusion, urinary retention, constipation.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
None.
None
May cause anticholinergic effects: confusion, hallucinations, urinary retention, constipation, blurred vision, heat stroke in hot weather,Use with caution in elderly patients due to CNS effects,Tardive dyskinesia: avoid abrupt withdrawal of antipsychotics when used for extrapyramidal symptoms,May exacerbate glaucoma, myasthenia gravis, gastrointestinal obstruction, and prostatic hypertrophy
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Known hypersensitivity to trihexyphenidyl,Narrow-angle glaucoma,Obstructive gastrointestinal disorders,Myasthenia gravis,Severe prostatic hypertrophy,Megaesophagus or esophageal achalasia
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
No significant food interactions are known. However, taking with food may reduce gastrointestinal upset. Avoid excessive consumption of anticholinergic-containing foods or beverages (e.g., certain teas) as it may potentiate side effects.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Procyclidine (Kemadrin) is Pregnancy Category C. Animal studies are insufficient; no adequate human studies. First trimester: Avoid unless benefit outweighs risk; potential anticholinergic effects may cause fetal tachycardia. Second and third trimesters: Use with caution; neonatal anticholinergic effects (e.g., ileus, respiratory depression) reported near term.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
Excretion into breast milk is unknown; M/P ratio not established. Due to potential anticholinergic effects (e.g., drowsiness, gastrointestinal disturbances) in the infant, avoid use during breastfeeding or use with caution. Monitor infant for anticholinergic side effects.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
No specific pharmacokinetic studies in pregnancy. Increased plasma volume and reduced gastrointestinal motility may alter absorption; however, no dose adjustment guidelines established. Use lowest effective dose. Monitor clinical response and adjust dosing based on anticholinergic side effects.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Kemadrin (procyclidine) is an anticholinergic agent used primarily for drug-induced parkinsonism and other extrapyramidal symptoms. Monitor for anticholinergic adverse effects, including dry mouth, blurred vision, urinary retention, and constipation. Use cautiously in elderly patients due to increased sensitivity. Avoid abrupt discontinuation to prevent withdrawal symptoms. May cause CNS effects such as dizziness or confusion.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,Avoid alcohol and other CNS depressants as they may increase drowsiness.,Report any vision changes, difficulty urinating, or severe constipation to your healthcare provider.,Use caution when driving or operating machinery until you know how this medication affects you.,Stay hydrated and use sugarless gum or hard candy to relieve dry mouth.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEMADRIN vs FLEXERIL, answered by our medical review team.
KEMADRIN is a Anticholinergic Antiparkinsonian that works by Centrally acting anticholinergic agent that blocks muscarinic receptors in the basal ganglia, reducing cholinergic overactivity and restoring dopamine-acetylcholine balance.. FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEMADRIN and FLEXERIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEMADRIN is: 2.5 mg orally three times daily, increased gradually to 5 mg three to four times daily if necessary; maximum 15-20 mg daily.. The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEMADRIN and FLEXERIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEMADRIN is classified as Category C. Procyclidine (Kemadrin) is Pregnancy Category C. Animal studies are insufficient; no adequate human studies. First trimester: Avoid unless benefit outweighs risk; potential anticho. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.